AIDSWEEKLY Plus; Monday, May 21, 2007
Staff Medical Writers

National Institutes of Health (NIH) Director Elias A. Zerhouni, M.D., and Secretary of the Department of Biotechnology in India, Maharaj K. Bhan, M.D., signed the Joint Statement on May 3, 2007, renewing this historic program for another five-year period.

"The Indo-U.S. Vaccine Action Program continues to demonstrate that international cooperation focused on outstanding research and the development of critically important public health tools can save millions of lives," says Dr. Zerhouni. "The U.S. government remains steadfast in its commitment to this program and its scientific vision."

Dr. Bhan, a former VAP grantee who currently oversees the government department that implements the program, says that the VAP has been one of India’s most important and successful international scientific collaborations since the program began in 1987. "A total of 35 collaborative research projects have been funded over the last two decades, and many talented young scientists have been trained through relationships fostered by this program," he notes.

VAP’s research priorities include acute respiratory illnesses, hepatitis, rotavirus diarrhea, cholera, leishmaniasis, typhoid, rabies, HIV/AIDS, tuberculosis, malaria and emerging and re-emerging infectious diseases.

Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), and Roger Glass M.D., Ph.D., NIH associate director for international research and director, Fogarty International Center, also attended the event and welcomed continuation of the program. On behalf of the U.S. government, NIAID manages the VAP and has provided scientific guidance since its inception.

"The widespread use of existing vaccines and the development of new vaccines are essential as we confront vaccine-preventable diseases globally," says Dr. Fauci.

Based on the success of VAP, several other NIH institutes and another agency of the U.S. Department of Health and Human Services, the Centers for Disease Control and Prevention, have signed similar bilateral agreements with the government of India.

"These collaborations clearly benefit both countries and the global biomedical and public health research community more broadly," notes Dr. Glass.

Many VAP-supported research projects have directly addressed critical health problems. Rotavirus is responsible for about 20 percent of diarrhea-related hospitalizations and 100,000 deaths in India each year. With VAP funding, Indian and American scientists discovered novel strains of rotavirus in Indian newborns. Further research confirmed that when these strains are used as a basis for candidate vaccines, the vaccines might protect against the disease. Drs. Bhan and Glass developed the candidate vaccine, which is being tested in large-scale clinical trials in India.

Other successful collaborations include the development of a new hepatitis C diagnostic test for Indian patients. As a demonstration of the program’s commitment to move from discovery to public health impact, VAP also will assist the commercial development of these diagnostic measures. This is especially important because currently available diagnostic methods that are reasonably effective in the United States have shown low specificity in India.

Recently, three VAP scientific missions to India discussed cooperation on HIV/AIDS, rabies and malaria. Since rabid animal bites and rabies-related human deaths are common in India, U.S. experts helped review the status of rabies prevention and recommended actions that might reduce the number of people who die. Efforts also are under way to develop collaboration on malaria vaccine research.

Keywords: HIV/AIDS Co-Infection, AIDS, Acquired Immunodeficiency Syndrome, Biomedical Engineering, Biotechnology, HIV, Human Immunodeficiency Virus Bacterial Infection, Marketing and Licensing Agreements, Rabies, Vaccines, Virology, U.S. National Institutes of Health.

This article was prepared by AIDS Weekly editors from staff and other reports.

2007-05-21
AW070509

Copyright © 2007 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.